Cargando…

Network meta‐analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant

The treatment scenario for newly‐diagnosed transplant‐ineligible multiple myeloma patients (NEMM) is quickly evolving. Currently, combinations of proteasome inhibitors and/or immunomodulatory drugs +/− the monoclonal antibody Daratumumab are used for first‐line treatment, even if head‐to‐head compar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Botta, Cirino, Gigliotta, Emilia, Paiva, Bruno, Anselmo, Rita, Santoro, Marco, Otero, Paula Rodriguez, Carlisi, Melania, Conticello, Concetta, Romano, Alessandra, Solimando, Antonio Giovanni, Cerchione, Claudio, Vià, Matteo Da, Bolli, Niccolò, Correale, Pierpaolo, Di Raimondo, Francesco, Gentile, Massimo, San Miguel, Jesus, Siragusa, Sergio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084226/ https://www.ncbi.nlm.nih.gov/pubmed/35794705 http://dx.doi.org/10.1002/hon.3041

Ejemplares similares

How I manage frontline transplant-eligible multiple myeloma in Italy
por: Montefusco, Vittorio, et al.
Publicado: (2020)

Molecular-Biology-Driven Frontline Treatment for Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Randomized Clinical Trials
por: Rizzuto, Andrea, et al.
Publicado: (2023)

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
por: Botta, Cirino, et al.
Publicado: (2021)

How we manage smoldering multiple myeloma
por: Romano, Alessandra, et al.
Publicado: (2020)

Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again
por: Plano, Federica, et al.
Publicado: (2023)

The Route of the Malignant Plasma Cell in Its Survival Niche: Exploring “Multiple Myelomas”
por: Solimando, Antonio Giovanni, et al.
Publicado: (2022)

Myeloid-Derived Suppressor Cells in Multiple Myeloma: Pre-Clinical Research and Translational Opportunities
por: Botta, Cirino, et al.
Publicado: (2014)

The molecular pathogenesis of multiple myeloma
por: Bolli, Niccolò, et al.
Publicado: (2020)

Effects of B-Cell Lymphoma on the Immune System and Immune Recovery after Treatment: The Paradigm of Targeted Therapy
por: Mancuso, Salvatrice, et al.
Publicado: (2022)

Immunosenescence and lymphomagenesis
por: Mancuso, Salvatrice, et al.
Publicado: (2018)

Host‐related factors and cancer: Malnutrition and non‐Hodgkin lymphoma
por: Mancuso, Salvatrice, et al.
Publicado: (2022)

Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities
por: Botta, Cirino, et al.
Publicado: (2021)

Tumor infiltration by chemokine receptor 7 (CCR7)(+) T-lymphocytes is a favorable prognostic factor in metastatic colorectal cancer
por: Correale, Pierpaolo, et al.
Publicado: (2012)

How I manage frontline transplant-ineligible multiple myeloma
por: Derudas, Daniele, et al.
Publicado: (2020)

Late onset of unilateral optic disk edema secondary to treatment with imatinib mesylate
por: Napolitano, Mariasanta, et al.
Publicado: (2017)

Paroxysmal nocturnal hemoglobinuria: When delay in diagnosis and long therapy occurs
por: Mancuso, Salvatrice, et al.
Publicado: (2018)

The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents
por: Romano, Alessandra, et al.
Publicado: (2017)

Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma
por: Meirson, Tomer, et al.
Publicado: (2022)

High Output Heart Failure in Multiple Myeloma: Pathogenetic Considerations
por: Carlisi, Melania, et al.
Publicado: (2022)

Calculated Whole Blood Viscosity and Albumin/Fibrinogen Ratio in Patients with a New Diagnosis of Multiple Myeloma: Relationships with Some Prognostic Predictors
por: Carlisi, Melania, et al.
Publicado: (2023)

Long-Term Remission Achieved by Ponatinib and Donor Lymphocytes Infusion in a Ph+ Acute Lymphoblastic Leukemia Patient in Molecular Relapse After Allogenic Stem Cell Transplant and Dasatinib: A Case Report
por: Botta, Cirino, et al.
Publicado: (2020)

Extracellular Vesicle microRNAs Contribute to the Osteogenic Inhibition of Mesenchymal Stem Cells in Multiple Myeloma
por: Raimondo, Stefania, et al.
Publicado: (2020)

The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep
por: Accurso, Vincenzo, et al.
Publicado: (2020)

Advantage of achieving deep response following frontline daratumumab-VTd compared to VRd in transplant-eligible multiple myeloma: multicenter study
por: Byun, Ja Min, et al.
Publicado: (2023)

Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection
por: Romano, Alessandra, et al.
Publicado: (2022)

P973: REAL-WORLD STUDY ON ADOPTION OF STANDARD OF CARE (SOC) FOR FRONTLINE TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA (FLTEMM) PATIENTS BETWEEN 2017 AND 2020/2021 ACROSS FRANCE, GERMANY, SPAIN, AND ITALY
por: Weisel, K., et al.
Publicado: (2022)

Inflammatory status affects the antitumor activity of poly-epitope-peptide vaccination against the thymidylate synthase in metastatic colo-rectal cancer patients enrolled in TSPP/VAC-1 Phase Ib trial
por: Correale, Pierpaolo, et al.
Publicado: (2015)

A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)
por: Chen, Yunxin, et al.
Publicado: (2021)

Multiple Myeloma in 2023 Ways: From Trials to Real Life
por: Fazio, Manlio, et al.
Publicado: (2023)

PB1987: DOMESTIC OPPORTUNITY IN HEAVILY PRETREATED MULTIPLE MYELOMA NOT ELIGIBLE TO HOSPITAL-BASED TREATMENT: ROLE OF POMALIDOMIDE-DEXAMETHASONE
por: Cerchione, C., et al.
Publicado: (2022)

FROM BENIGN TO MALIGNANT DISEASE
por: Bolli, Niccolò
Publicado: (2022)

Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies
por: Mina, Roberto, et al.
Publicado: (2020)

Immunological Dysregulation in Multiple Myeloma Microenvironment
por: Romano, Alessandra, et al.
Publicado: (2014)

Clinical Phenotype and Response to Different Lines of Therapy in Elderly with Immune Thrombocytopenia: A Retrospective Study
por: Mancuso, Salvatrice, et al.
Publicado: (2020)

A Journey Through Myeloma Evolution: From the Normal Plasma Cell to Disease Complexity
por: Da Vià, Matteo C., et al.
Publicado: (2020)

Genomics of Smoldering Multiple Myeloma: Time for Clinical Translation of Findings?
por: Lionetti, Marta, et al.
Publicado: (2021)

Ferritin Metabolism Reflects Multiple Myeloma Microenvironment and Predicts Patient Outcome
por: Plano, Federica, et al.
Publicado: (2023)

Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev)
por: Pastina, Pierpaolo, et al.
Publicado: (2017)

Behavioral Restriction Determines Left Attentional Bias: Preliminary Evidences From COVID-19 Lockdown
por: Lardone, Anna, et al.
Publicado: (2021)

Lenalidomide and Pomalidomide Improve Function and Induce FcγRI/CD64 in Multiple Myeloma Neutrophils
por: Romano, Alessandra, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pd0qf2v0qng8n91jjcup3lrstq